Electra Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
230 E Grand Ave Ste S100, South San Fran...Phone Number
(888) 743-2290Website
www.electra-therapeutics.comRevenue
-Industry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer. The companys lead product candidate, ELA026, is a first in class monoclonal antibody that targets signal regulatory proteins (SIRP) on immune cells to selectively deplete pathological myeloid cells and T lymphocytes. ELA026 is currently in pivotal development for secondary hemophagocytic lymphohistiocytosis (sHLH) and is also being evaluated in additional indications. Electra is further advancing a second SIRP-targeted program, ELA822, designed to selectively deplete activated T lymphocytes, with broad potential across immunology and inflammation (I&I).Explore more
Electra Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Electra Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Electra Therapeutics is spiking on competitors!
Check if Electra Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Electra Therapeutics recently announced quarterly report
Electra Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Electra Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Electra Therapeutics launches new products
Funding: Get notified immidiatlly once Electra Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Electra Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Electra Therapeutics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Electra Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Electra Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Electra Therapeutics.
Electra Therapeutics financials insights
Gather financial insights about Electra Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series B
$84M
2025
Series C
$183M
Stock/Share Issuance
$134.2M
Electra Therapeutics Tech Stack
A closer look at the technologies used by Electra Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
, according to a high-level source in accounting, is in the midst of initiatives related to technical accounting. The organization is currently evaluating NetSuite. Electra Therapeutics will be increasing funding to support these efforts. The organization is focusing on specific tax and accounting topics which require audit review as part of these initiatives.
Spending/Investment, Accounting, Financial Planning, Audit, Financial Reporting, Internal Audit & Control, Finance
Pain Point
Project
, according to a high-level source in accounting, is experiencing challenges related to project accounting.
Pain Point, Accounting, Financial Reporting, Finance
Project
Accounting, Financial Reporting, Finance
Electra Therapeutics News & Media
Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases
Second clinical-stage asset generated from the company’s proprietary library of SIRP-targeted antibodies Second clinical-stage asset generated from the company’s proprietary library of SIRP-targeted antibodiesElectra Therapeutics Appoints Chris Clark, CFA, to Chief Financial Officer
SOUTH SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the promotion of Chris Clark, CFA, to Chief Financial Officer. Mr. Clark joined Electra in December 2025 as Executive Vice President, Strategy and Finance, bringing with him more than two decades of life sciences investment experience.Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies
Phase 1 study builds on early signals of anti-tumor activity in patients with refractory T and B cell lymphomasElectra Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer, today announced that it will present at the 44th annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, CA.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Electra Therapeutics
Sign Up For FreeTo access detailed company insights
Electra Therapeutics is a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and cancer. The companys lead product candidate, ELA026, is a first in class monoclonal antibody that targets signal regulatory proteins (SIRP) on immune cells to selectively deplete pathological myeloid cells and T l... Read More
